cincorlogo.jpg
CinCor Pharma, Inc., Doses First Patient in HALO, a Phase 2 Clinical Trial Evaluating CIN-107, a Selective Aldosterone Synthase Inhibitor, in Patients with Uncontrolled Hypertension and High Plasma Aldosterone
09 déc. 2021 08h00 HE | CinCor Pharma, Inc.
CINCINNATI, Dec. 09, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), announced today the dosing of the first patient in its Phase 2 clinical trial evaluating CIN-107, a highly selective,...
cincorlogo.jpg
CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects
20 oct. 2020 08h00 HE | CinCor Pharma, Inc.
CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that...